Treatment of uncomplicated reflux disease

World Journal of Gastroenterology

Volumn 11, Issue 28, 2005, Pages 4291-4299

  Labenz, Joachim ^a   Malfertheiner, Peter ^b  

^a Ev Jung Stilling Krankenhaus   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Erosive reflux disease; Non erosive reflux disease; Proton pump inhibitor; Uninvestigated reflux disease

Indexed keywords

ANTACID AGENT; BACLOFEN; CISAPRIDE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR AGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SEROTONIN UPTAKE INHIBITOR; SUCRALFATE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTIREFLUX OPERATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOSCOPIC SURGERY; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; PATHOPHYSIOLOGY; PATIENT SELECTION; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REFLUX ESOPHAGITIS; RELAPSE; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY;

EID: 23244450069     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i28.4291     Document Type: Review

References (91)

1. Locke GR, Talley J, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456
2. Quigley EM. Non-erosive reflux disease (NERD); part of the spectrum of gastro-oesophageal reflux, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13 (Suppl 1): S13-18
3. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-1907
4. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw N, Talley NJ. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44(Suppl 2): S1-S16
5. Dent J. Management of reflux disease. Gut 2002; 50(Suppl 4): iv67-71
6. Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004; 53(Suppl 4): iv1-24
7. Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-208
8. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-545
9. Kulig M, Nocon M, Vieth M, Leodolter A, Jaspersen D, Labenz J, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004; 57: 580-589
10. Junghard O, Carlsson R, Lind T. Sufficient control of heart-burn in endoscopy-negative gastro-oesophageal reflux disease trials. Scand J Gastroenterol 2003; 38: 1197-1199
11. Bytzer P, Blum AL. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 389-398
12. Mäntynen T, Färkkilä M, Kunnamo I, Mecklin JP, Voutilainen M. The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: 1-year cross sectional study in a referral area with 260 000 inhabitants. Am J Gastroenterol 2002; 97: 2524-2529
13. Koop H. Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy 2004; 36: 103-109
14. Blustein PK, Beck PL, Meddings JB, Van Rosendaal GM, Bailey RJ, Lalor E, Thomson AB, Verhoef MJ, Sutheland LR. The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms. Am J Gastroenterol 1998; 93: 2508-2512
15. Jones MP. Acid suppression in gastro-oesophageal reflux disease: Why? How? How much and when? Postgrad Med J 2002; 78: 465-468
16. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51: 885-892
17. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-664
18. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 mg once daily, or ranitidine 150 milligrams twice daily, evaluated as initital therapy for the relief of symptoms in general practice. Scand J Gastroenterol 1997; 32: 965-973
19. Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004; 19(Suppl 1): 28-34
20. Lauritsen K. Management of endoscopy-negative reflux disease: progress with short-term treatment. Aliment Pharmacol Ther 1997; 11(Suppl 2): 87-92
21. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, Junghard O, Lauritsen K, Lundell L, Pedersen SA, Stubberöd A. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-979
22. Richter JE, Kovacs TOG, Greski-Rose PA, Huang B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999; 13: 795-804
23. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003; 18: 875-883
24. Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, Venables T, Green J, Bigard MA, Mössner J, Junghard O. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20: 413-421
25. Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 59-66
26. Fass R, Ofman JJ, Grainek IM, Johnson C, Camargo E, Sampliner RE, Fennerty MB. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159: 2161-2168
27. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the"sensitive oesophagus". Gut 1997; 40: 587-590
28. Kahrilas PJ. Refractory heartburn. Gastroenterology 2003; 124: 1941-1945
29. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I. Gastro-oesophageal reflux disease (GORD) in primary care - an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119-124
30. Bardhan KD, Müller-Lissner S, Bigard MS, Bianchi Porro G, Ponce J, Hosie J, Scott M, Wein DG, Gillon KRW, Peacock RA, Fulton C. Symptomatic gastro-oesophageal reflux disease: double-blinded controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 1999; 318: 502-507
31. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopöulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395-407
32. Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with continuous omeprazole strategies. Pharmacoeconomics 2002; 20: 267-277
33. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberöd A, Eriksson G, Carlsson R, Junghard O. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-914
34. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oseophageal reflux disease: a controlled trial of on-demand therapy for 6 mo. Aliment Pharmacol Ther 2001; 15: 347-354
35. Talley NJ, Venables TL, Green JR, Armstrong D, O'Kane KP, Giaffer M, Bardhan KD, Carlsson RG, Chen S, Hasselgren GS. Esomeprazole 40 mg and 20 mg is efficacious in the longterm management of patients with endoscopy-negative gastrooesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 mo. Eur J Gastroenterol Hepatol 2002; 14: 857-863
36. Bayerdörffer E, Sipponen P, Bigard M, Weiss W, Mearin F, Rodrigo L, Dominguez-Munoz J, Grundling H, Nauclér E, Svedberg L, Keeling N, Eklund S. Esomeprazole 20 mg continous versus on demand treatment of patients with endoscopy-negative reflux disease (ENRD). Gut 2004; 53 (Suppl 4): A106
37. Tsai HH, Chapman R, Shepherd A, McKeith D, Anderson M, Vearer D, Duggan S, Rosen JP. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study. Aliment Pharmacol Ther 2004; 20: 657-665
38. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92
39. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche P, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-180
40. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-665
41. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-583
42. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauclér E, Eklund S. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739-746
43. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810
44. Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, Meyer-Sabellek W, Junghard O, Stolte M. Prognostic influence of Barrett's oesophagus and of H pylori infection on healing auf erosive GORD and symptom resolution in non-erosive GORD: Report from the ProGORD study. Gut 2005; 54: 746-751
45. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-16
46. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1729-1736
47. Vakil N, Fennerty MB. Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer. Aliment Pharmacol Ther 2003; 18: 559-568
48. Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencly JL. Comparing lansoprazole and omeprazole in on-set of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001; 96: 3089-3098
49. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51(Suppl 1): 59-67
50. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S, Noguchi K, Hamada S, Noguchi M, Shimosegawa T. The effects of lansoprazole on erosive resflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965-973
51. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomperazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-2620
52. Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 2004; 24: 1-7
53. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249-1258
54. Fennerty MB, Johanson J, Hwang C, Hoyle P, Sostek M. Esomeprazole 40 mg versus lansoprazole 30 mg in healing and symptom relief in patients with moderate to severe erosive oesophagitis (Los Angeles C & D). Gut 2004; 53(Suppl 4): A111-112
55. Labenz J, Armstrong D, Katelaris P, Schmidt S, Nauclér E, Eklund S. Analysis of healing associated with 4 weeks' esomperazole 40 mg treatment relative to lansoprazole 30 mg and pantoprazole 40 mg in patients with all grades of erosive esophagitis. Gut 2004; 53(Suppl 4): A105
56. Gillessen A, Beil W, Modlin IM, Gatz G, Hole U. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004; 38: 332-340
57. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficay in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003; 18: 587-594
58. Tinmouth JM, Steele LS, Tomlinson G, Glazier RH. Are claims of equivalency in digestive disease trials supported by the evidence? Gastroenterology 2004; 126: 1700-1710
59. Fass R, Thomas S, Traxler B, Sostek M. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patients who failed standard dose PPI versus switching to a different PPI. Gastroenterology 2004; 126: A37
60. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-1240
61. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 545-550
62. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-632
63. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, D'Amico D, Hamelin B. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-mo, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-935
64. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, D'Amico D, Hamelin B. Esomeprazole once daily for 6 mo is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27-34
65. Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002; 37: 642-647
66. Sjöstedt S, Befrits R, Sylvan A, Carling L, Harthon C, Modin S, Stubberöd A, Toth E, Lind T. On demand versus continuous treatment with esomeprazole (ESO) 20 mg once daily in subjects with healed erosive esophagitis (EE) after initial healing with ESO 40 mg once daily. An open, randomised, Swedish multicenter study. Gut 2004; 53(Suppl 4): A68
67. Richter JE, Fraga P, Mack M, Sabesin SM, Bochenek W. The Pantoprazole US GERD Study Group. Prevention of erosive esophagitis relapse with pantoprazole. Aliment Pharmacol Ther 2004; 20: 1-9
68. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Sandro Mela G, Pilotto A, Blebani M, Davi G. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-1110
69. You JH, Lee AC, Wong SC, Chan FK. Low-dose or standard dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2003; 17: 785-792
70. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, Swanson KM, Sonnenberg A. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121: 1095-1100
71. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98: 1940-1944
72. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-669
73. Lauritsen K, Devière J, Bigard MA, Bayerdörffer E, Mózsik G, Murray F, Kristjánsdóttir S, Savarino V, Vetvik K, De Freitas D, Orive V, Rodrigo L, Fried M, Morris J, Schneider H, Eklund S, Larkö A. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333-341
74. DeVault KR, Liu S, Hoyle P, Sostek M. Esomeprazole 20 mg versus lansoprazole 15 mg for maintenance of healing of erosive esophagitis. Am J Gastroenterol 2004; 99(Suppl): S6-S7
75. Labenz J, Armstrong D,, Katelaris P, Schmidt S, Adler J, Eklund S. A comparison of esomeprazole and pantoprazole for maintenance treatment of healed erosive esophagitis. Gut 2004; 53(Suppl 4): A108
76. Labenz J, Armstrong D, Katelaris P, Schmidt S, Eklund S. The effect of Helicobacter pylori status on maintenance therapy for healed erosive esophagitis with esomeprazole 20 mg or pantoprazole 20 mg. Helicobacter 2004; 9: 544
77. Labenz J. Protagonist: Should we eradicate Helicobacter pylori before long term antireflux therapy? Gut 2001; 49: 614-616
78. Freston JW. Antagonist: Should we eradicate Helicobacter pylori before long term antireflux therapy? Gut 2001; 49: 616-617
79. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-1126
80. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
81. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Liedman B, Hatlebakk JG, Julkonen R, Levander K, Carlsson J, Lamm M, Wiklund I. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 172-179
82. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Lamm M, Blomqvist A, Hatlebakk JG, Janatuinen E, Levander K, Nyström P, Wiklund I. Long-term management of gastrooesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. Eur J Gastroenterol Hepatol 2000; 12: 879-887
83. Arguedas MR, Heudebert GR, Klapow JC, Centor RM, Eloubeidi MA, Wilcox CM, Spechler SJ. Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophagealen reflux disease: the value of long-term data collection. Am J Gastroenterol 2004; 99: 1023-1028
84. Myrvold HE, Lundell L, Miettinen P, Pedersen SA, Liedman B, Hatlebakk J, Julkunen R, Levander K, Lamm M, Mattson C, Carlsson J, Stalhammar NO. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut 2001; 49: 488-494
85. Freston JW, Triadafilopoulos G. Review article: approaches to the long-term management of adults with GERD - proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? Aliment Pharmacol Ther 2004; 19(Suppl 1) 35-42
86. Arts J, Tack J, Galmiche JP. Endoscopic antireflux procedures. Gut 2004; 53: 1207-1214
87. Corley DA, Katz P, Wo J, Stefan A, Patti M, Rothstein R, Edmundowicz S, Kline M, Mason R, Wolfe MM. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003; 125: 668-676
88. Dent J, Talley NJ. Oveview: initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17(Suppi 1): 53-57
89. Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 2001; 96: 1704-1710
90. Armstrong D, Barkun AN, Chiba N, Veldhuyzen van Zanten S, Thomson ABR, Smyth S, Chakraborty B, Sinclair P. 'Start high' - A better acid suppression strategy for heartburn-dominant uninvestigated dyspepsia (DU) in primary care practice (PCP) - the CADET-HR study. Gastroenterology 2002; 122: A472
91. Meineche-Schmidt V, Hauschildt Juhl H, Ostergaard JE, Luckow A, Hvenegaard A. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004; 19: 907-915